Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
Salah-Eddin Al-Batran(Goethe University Frankfurt), Timo Gaiser(Heidelberg University), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Georg Martin Haag(Heidelberg University), Vera Heuer(St. Anna Hospital), Christina Kopp(Krankenhaus Nordwest), Claus Bolling(Agaplesion Markus Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Thomas J. Ettrich(Universität Ulm), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Udo Lindig(Jena University Hospital), Stefan Angermeier(Klinikum Ludwigsburg), Jorge Riera Knorrenschild(Philipps University of Marburg), Michael Schenk(Krankenhaus Barmherzige Brüder), Albrecht Kretzschmar(Roche (Switzerland)), Sylvie Lorenzen(Technical University of Munich), Alexander Siebenhuener(University Hospital Zurich), Claudia Pauligk(Goethe University Frankfurt)
Cited by 96
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k